Header Logo

Connection

Joan Lo to Diphosphonates

Back to Details
This is a "connection" page, showing publications Joan Lo has written about Diphosphonates.
Joan Lo
Connection Strength
6.963
Diphosphonates
  1. The Epidemiology of Metatarsal Fractures Among Older Females With Bisphosphonate Exposure. J Foot Ankle Surg. 2020 Mar - Apr; 59(2):269-273.
    View in: PubMed
    Score: 0.675
  2. Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure. Osteoporos Int. 2019 Dec; 30(12):2515-2520.
    View in: PubMed
    Score: 0.655
  3. Using Pharmacy Data and Adherence to Define Long-Term Bisphosphonate Exposure in Women. J Manag Care Spec Pharm. 2019 Jun; 25(6):719-723.
    View in: PubMed
    Score: 0.641
  4. Predicting Adherence and Persistence with Oral Bisphosphonate Therapy in an Integrated Health Care Delivery System. J Manag Care Spec Pharm. 2017 Apr; 23(4):503-512.
    View in: PubMed
    Score: 0.551
  5. Changing Patterns in Oral Bisphosphonate Initiation in Women between 2004 and 2012. J Am Geriatr Soc. 2017 03; 65(3):656-658.
    View in: PubMed
    Score: 0.545
  6. The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Bone. 2016 Apr; 85:142-7.
    View in: PubMed
    Score: 0.506
  7. Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy. Bone. 2012 Sep; 51(3):524-7.
    View in: PubMed
    Score: 0.394
  8. Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. J Oral Maxillofac Surg. 2012 Aug; 70(8):1844-53.
    View in: PubMed
    Score: 0.393
  9. Oral health considerations in older women receiving oral bisphosphonate therapy. J Am Geriatr Soc. 2011 May; 59(5):916-22.
    View in: PubMed
    Score: 0.366
  10. Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. J Oral Maxillofac Surg. 2010 Sep; 68(9):2232-40.
    View in: PubMed
    Score: 0.349
  11. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010 Feb; 68(2):243-53.
    View in: PubMed
    Score: 0.328
  12. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg. 2009 Jul; 67(7):1363-72.
    View in: PubMed
    Score: 0.322
  13. Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen. Breast Cancer Res Treat. 2016 Apr; 156(2):379-89.
    View in: PubMed
    Score: 0.257
  14. Osteoporosis and Fracture Risk among Older US Asian Adults. Curr Osteoporos Rep. 2023 10; 21(5):592-608.
    View in: PubMed
    Score: 0.214
  15. Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years. BMC Musculoskelet Disord. 2020 Dec 03; 21(1):801.
    View in: PubMed
    Score: 0.178
  16. Bisphosphonate Treatment Beyond 5 Years and Hip Fracture Risk in Older Women. JAMA Netw Open. 2020 12 01; 3(12):e2025190.
    View in: PubMed
    Score: 0.178
  17. Determinants of Oral Bisphosphonate Use Beyond 5 Years. J Manag Care Spec Pharm. 2020 Feb; 26(2):197-202.
    View in: PubMed
    Score: 0.168
  18. Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy. Breast Cancer Res Treat. 2018 Apr; 168(2):523-530.
    View in: PubMed
    Score: 0.145
  19. Clinical correlates of atypical femoral fracture. Bone. 2012 Jul; 51(1):181-4.
    View in: PubMed
    Score: 0.097

© 2024 Kaiser Permanente